China Resources Pharmaceutical Group Limited (Stock Code: 3320) has released subsidiary Dong-E-E-Jiao’s unaudited financial results for the nine months ended 30 September 2025. Dong-E-E-Jiao is listed on the Shenzhen Stock Exchange and is effectively controlled by the Group at approximately 23.50%.

According to the announcement, Dong-E-E-Jiao recorded revenue of RMB4.77 billion for the period, compared to RMB4.57 billion in the same period of 2024. Net profit stood at RMB1.28 billion, up from RMB1.15 billion in the same period last year. As of 30 September 2025, total assets amounted to RMB12.75 billion, while total liabilities were RMB2.78 billion. Owner’s equity reached RMB9.97 billion. The unaudited report also showed a net increase in cash and cash equivalents of RMB510.21 million over the nine-month period.

The unaudited financial statements were prepared under PRC Generally Accepted Accounting Principles and may require adjustments upon auditing. The released figures pertain solely to Dong-E-E-Jiao and should not be taken to represent the entire Group’s performance. The official announcement is available on the Shenzhen Stock Exchange website.